includes adherence to the European Medicines Agency (EMA) requirements, as well as considerations that fall under the purview of the European Commission.

Drug-device combinations may include products such as pre-filled syringes, inhalers, or drug-coated stents. Each component in these systems has distinctive regulatory avenues that must be navigated to ensure compliance. Key documents, including ISO standards (e.g., ISO 13485 for Quality Management Systems), and the GSPR detailed in Annex I of the EU MDR, serve as key references for regulatory professionals. Understanding GSPR is vital since it outlines the essential performance and safety requirements of devices, which must be demonstrated for all medical devices marketed in the EU.

Step 2: Initial Document Preparation for GSPR Mapping

Preparation is critical when beginning your GSPR mapping. Start with the development of a comprehensive documentation plan, which should include all necessary records concerning the drug-device combination. This will typically cover product design history, risk assessment reports, and existing test results. Each of these documents will play a pivotal role in the subsequent steps of the GSPR mapping process.

• Product Design History: Document all aspects of device and drug design, including intended use and claims.
• Device Specifications: Prepare specifications for both components within the combination product — the drug and device.
• Risk Assessment Reports: Using harmonized risk management standards, conduct a thorough risk assessment, linking hazards associated with the device to potential clinical outcomes.
• Clinical Investigation Data: For combination products involving novel therapeutics or innovative devices, compile relevant clinical data that supports safety and efficacy claims.

This foundational step lays the groundwork for effective GSPR mapping and enables a systematic review of product components through their respective regulatory lenses.

Step 3: Conducting GSPR Mapping with an Evidence Matrix

The core of the GSPR mapping process is to utilize an Evidence Matrix. This tool helps frame the information necessary to demonstrate compliance with GSPRs effectively. An Evidence Matrix typically contains columns for GSPR clauses from the EU MDR, applicable testing or documentation required, and existing data that corresponds to each requirement. Begin by transcribing each applicable GSPR clause into the matrix.

Next, for each GSPR clause:

• Identify the evidence required to demonstrate conformity.
• List existing data or tests that provide this evidence.
• Document any testing gaps or additional information needed to meet GSPR.

Ensure that Traceability is maintained, linking the claims made in your regulatory submissions back to the evidence documented within the matrix. This matrix will serve as a pivotal tool during both the submission and the review phases.

Step 4: Interaction with Notified Bodies

Communicating with Notified Bodies is an essential aspect of compliance in the drug-device regulatory landscape. As part of your GSPR mapping, it’s important to engage with appropriate notified bodies early in the process, particularly with those experienced in both drug and device evaluations. This will provide insights into the specific expectations surrounding GSPR compliance.

Prepare for the Notified Body interaction by:

• Submitting your Evidence Matrix for preliminary review.
• Addressing questions and issues that arise from this initial review to ensure clarity and compliance with GSPRs.
• Gathering requisite documentation to substantiate all claims made in your matrix.

This proactive strategy will enable a smoother review process, reduce the likelihood of contentious issues arising later, and facilitate robust understanding from both parties regarding regulatory expectations.

Step 5: Submission Preparation for Regulatory Review

Once the Evidence Matrix is completed and feedback has been integrated following discussions with the Notified Body, you will move into the preparation of the regulatory submission. The submission should adhere to the strict guidance outlined in the EU MDR, ensuring that all required documentation is complete and adequately detailed. The submission must include, at a minimum:

• Technical Documentation: Provide evidence that demonstrates compliance with the applicable GSPRs outlined in Annex II of the EU MDR.
• Clinical Evaluation Reports: Establish that the device performs safely and effectively when used as intended.
• Quality Management System Documentation: Provide an overview of quality management processes in place that govern manufacturing and quality assurance.

Ensure that your submission format is consistent with expectations set forth by both the Notified Bodies and the broader regulatory framework. Adhere strictly to submission deadlines and formats, including any electronic submissions required by regulatory bodies such as EUDAMED for registration.

Step 6: Engaging in the Review Process

Following submission, the review process ensues. During this phase, regulatory professionals should remain engaged and responsive. Expect to answer queries from the Notified Body and provide any additional information they require to facilitate a thorough evaluation. Key actions include:

• Timely Responses: Address any inquiries promptly, which assists in expediting the review period.
• Continuous Monitoring: Monitor the status of the review through agreed-upon channels, ensuring not to miss any updates that may necessitate further action on your part.
• Collaboration: Maintain open lines of communication with the Notified Body throughout the process.

Being proactive during the review process can significantly enhance the likelihood of receiving favorable opinions from the Notified Body regarding the safety and performance of your drug-device system.

Step 7: Post-Approval Commitments and Pharmacovigilance Requirements

The final step in the GSPR mapping process involves post-approval commitments and ensuring that ongoing compliance with regulatory requirements is maintained. This includes establishing robust post-market surveillance systems to monitor the performance of the drug-device combination after it has received CE marking. Essential components of this step include:

• Updating the Evidence Matrix: Post-market data must be continuously added to your Evidence Matrix, demonstrating ongoing compliance with GSPRs.
• Engaging in Pharmacovigilance Activities: Set up processes for reporting adverse events and ensuring that any safety concerns are swiftly addressed.
• Regular Reporting: Submit relevant reports to regulatory authorities periodically to confirm the continued safety and efficacy of the product.

Post-approval activities should be viewed as part of the lifecycle management of your product, requiring rigorous oversight and commitment to quality and safety standards.